Psoriasis and metabolic disease: epidemiology and pathophysiology
about
Immunology of psoriasisPutting together the psoriasis puzzle: an update on developing targeted therapiesSkin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivoPharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registriesActivation of PPARbeta/delta causes a psoriasis-like skin disease in vivo.Exploring the link between cadmium and psoriasis in a nationally representative sampleThe risk of stroke in patients with psoriasisVitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist.Diet and weight loss as a treatment for psoriasis.Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.Anti-psoriatic activity of Givotia rottleriformis in ratsSpectral imaging reveals microvessel physiology and function from anastomoses to thromboses.The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities.The brain-skin connection: role of psychosocial factors and neuropeptides in psoriasis.Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies.Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries.Resolved psoriasis lesions retain expression of a subset of disease-related genesPrevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006.LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment.Alkyloxy carbonyl modified hexapeptides as a high affinity compounds for Wnt5A protein in the treatment of psoriasis.Systemic role for vitamin d in the treatment of psoriasis and metabolic syndromeSystemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot studyThe association of psoriasis and elevated blood lipids in overweight and obese children.Psoriasis and dyslipidemia.Cardiovascular comorbiditiy in psoriasisPsoriasis and metabolic syndrome.Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis.Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom.Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingMagnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment.Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 yearsEvaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician.Psoriasis and cardiovascular risk: strength in numbers, part II.The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.Metabolic syndrome in patients with psoriatic disease.The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center.Cardiometabolic risk in psoriasis: differential effects of biologic agents.
P2860
Q26995800-300A7D27-60EB-4A2B-B101-D487CF718D5EQ27026785-AB1C9F77-2327-4B47-973D-38587E651A7CQ28483670-62342CB2-D3F6-4515-9C65-758668F784C4Q28730205-357D218F-9004-47AE-93DD-55EABB3A160DQ33543078-DBDE36A9-17F1-49D8-861A-7B446AFDC224Q33687498-05BE1DBB-3D63-4B32-8512-82AE7D01C675Q33831094-439C47A6-BDA1-468F-8D0D-5AC82FACA4EFQ33841808-661C3393-28FA-4EE5-B86A-8414118EEECDQ33940511-ED2F95C5-D6C0-4188-8B18-D4CB59AC1381Q33951592-895E7D69-48D1-4F73-9A4F-79E13A1A88A1Q33987266-E4140739-4993-4425-979C-B2A19F6AEB65Q34049847-305439A3-08AC-44BD-AEC6-FDCC255C6BBBQ34076431-B7FF9902-25B6-4B70-B249-DF1255775F46Q34080687-7E63B9A0-6D79-4492-B08C-940AD28AC8F8Q34253312-E4F9B3F0-AF0D-44FC-862A-25A996382E67Q34381490-44B9A26D-AB4E-4D43-B76C-9406676E2BE3Q34420240-E166E819-1690-4D12-B0B5-1FAD209587D4Q34490905-E39B9F0F-759A-48EF-8E40-C4D767FC4845Q34785993-737F7EE0-33CD-4C30-9795-93DBCC368AC5Q34855603-6432B784-0158-4CBC-AF1E-E7132E913719Q35033149-39159171-3049-4E06-9BAB-CAE744F386D9Q35089915-5E73D730-1B83-4BFE-8A24-FE6AD9C71250Q35171276-E5537A6D-0108-4A03-A86C-0E1BFA240D76Q35199755-E8581CA6-51D9-4642-8089-BDB599F35DFBQ35263254-2B096576-48C4-42A6-9839-612C5E34DDBCQ35564655-96874C46-1E16-42AD-A149-0CC4939A9E18Q35601338-75E9C639-1931-4903-BF78-8FD94DE48BD5Q35620308-34E1EAE6-CB9C-4793-9C51-38B2FDD71B57Q35753936-0FBAAD7C-314C-4B4B-9126-B17CD79B86ABQ35770123-9AF4526E-8E5C-47C0-93A0-C1001EA34910Q35822379-CE1CD63C-C513-49B5-A318-538AECB9B100Q36036715-7F71D23C-2C84-4529-890E-753E39C8B177Q36048427-75CA0738-CD15-4503-95C4-33EE0C5AFD19Q36091617-ED0AAB34-7D08-4820-BC2C-2DC303737E47Q36185077-738C5333-7270-4BBE-B019-505C11DA71C6Q36602668-4A334330-5539-422B-9094-DD4B2CABFEE2Q36897095-D77BF58F-493F-4287-94C0-41D90E5D670AQ37040371-1DF93C7B-D0B1-403B-922A-7F3F5905116FQ37118037-2CF74EF9-3192-427C-813D-9A90EFBC5BDFQ37145684-3544BA5F-2582-4615-95F1-62B491518A8A
P2860
Psoriasis and metabolic disease: epidemiology and pathophysiology
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Psoriasis and metabolic disease: epidemiology and pathophysiology
@en
Psoriasis and metabolic disease: epidemiology and pathophysiology.
@nl
type
label
Psoriasis and metabolic disease: epidemiology and pathophysiology
@en
Psoriasis and metabolic disease: epidemiology and pathophysiology.
@nl
prefLabel
Psoriasis and metabolic disease: epidemiology and pathophysiology
@en
Psoriasis and metabolic disease: epidemiology and pathophysiology.
@nl
P2860
P1476
Psoriasis and metabolic disease: epidemiology and pathophysiology
@en
P2093
Rahat S Azfar
P2860
P304
P356
10.1097/BOR.0B013E3283031C99
P577
2008-07-01T00:00:00Z